07:00 , Aug 24, 2015 |  BC Week In Review  |  Clinical News

AVN-211: Phase IIb data

A double-blind, Russian Phase IIb trial in 80 schizophrenic patients in incomplete remission on stable antipsychotic therapy showed that once-daily oral AVN-211 missed the primary endpoint of improving PANSS total score from baseline to week...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Clinical News

AVN-211: Phase IIb started

Avineuro began a Russian Phase IIb trial to evaluate 4 and 8 mg AVN-211 once daily for 6 weeks in 80 patients with schizophrenia in a state of a partial remission on stable antipsychotic therapy....
07:00 , Oct 28, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); schizophrenia Serotonin (5-HT6) receptor In vitro and rat studies suggest that a class of...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

AVN-211: Phase I started

Avineuro began a placebo-controlled, dose-escalation, European Phase I trial to evaluate 2 and 4 mg/day of oral AVN-211. Avineuro Pharmaceuticals Inc., San Diego, Calif.   Product: AVN-211   Business: Neurology   Molecular target: Serotonin (5-HT6) receptor...